Suzanne Leijen

1.6k total citations
19 papers, 1.3k citations indexed

About

Suzanne Leijen is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Suzanne Leijen has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Molecular Biology and 2 papers in Organic Chemistry. Recurrent topics in Suzanne Leijen's work include PI3K/AKT/mTOR signaling in cancer (7 papers), Melanoma and MAPK Pathways (6 papers) and Cancer-related Molecular Pathways (6 papers). Suzanne Leijen is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (7 papers), Melanoma and MAPK Pathways (6 papers) and Cancer-related Molecular Pathways (6 papers). Suzanne Leijen collaborates with scholars based in Netherlands, United States and Switzerland. Suzanne Leijen's co-authors include Jan H.M. Schellens, Jos H. Beijnen, Erik van Werkhoven, Dick Pluim, Enzo Alessio, Matthijs M. Tibben, Paul Baas, Sjaak A. Burgers, Shelonitda Rose and Gianni Sava and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Suzanne Leijen

19 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suzanne Leijen Netherlands	13	770	728	227	98	93	19	1.3k
Terence R. Jones United States	17	665 0.9×	401 0.6×	202 0.9×	253 2.6×	68 0.7×	37	1.0k
Masashi Aonuma Japan	11	1.2k 1.5×	875 1.2×	128 0.6×	122 1.2×	118 1.3×	14	1.5k
G. Mangold Germany	17	661 0.9×	437 0.6×	183 0.8×	118 1.2×	132 1.4×	46	1.2k
Morwenna Muir United Kingdom	20	753 1.0×	940 1.3×	500 2.2×	163 1.7×	125 1.3×	38	1.8k
F. Zunino Italy	19	565 0.7×	514 0.7×	119 0.5×	123 1.3×	139 1.5×	33	1.2k
Neil Johnson United States	20	1.4k 1.8×	974 1.3×	95 0.4×	177 1.8×	222 2.4×	42	1.9k
Sharon K. Rudolph United States	9	497 0.6×	312 0.4×	207 0.9×	97 1.0×	264 2.8×	12	966
Lorraine A. Cazenave United States	6	558 0.7×	847 1.2×	112 0.5×	95 1.0×	102 1.1×	7	1.3k
Chengying Xie China	20	777 1.0×	866 1.2×	125 0.6×	207 2.1×	447 4.8×	58	1.8k
Darin Smith United States	12	705 0.9×	316 0.4×	99 0.4×	60 0.6×	85 0.9×	13	978

Countries citing papers authored by Suzanne Leijen

Since Specialization

Citations

This map shows the geographic impact of Suzanne Leijen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Leijen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Leijen more than expected).

Fields of papers citing papers by Suzanne Leijen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Leijen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Leijen. The network helps show where Suzanne Leijen may publish in the future.

Co-authorship network of co-authors of Suzanne Leijen

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Leijen. A scholar is included among the top collaborators of Suzanne Leijen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Leijen. Suzanne Leijen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Delord, Jean‐Pierre, Antoîne Italiano, Ahmad Awada, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Targeted Oncology. 16(1). 37–46. 8 indexed citations

Lebbé, Célèste, Antoîne Italiano, Nadine Houédé, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology. 16(1). 47–57. 10 indexed citations

Leijen, Suzanne, Robin M.J.M. van Geel, Gabe S. Sonke, et al.. (2016). Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. Journal of Clinical Oncology. 34(36). 4354–4361. 239 indexed citations

Leijen, Suzanne, Robin M.J.M. van Geel, Anna C. Pavlick, et al.. (2016). Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 34(36). 4371–4380. 195 indexed citations

Leijen, Suzanne, Robin M.J.M. van Geel, Gabe S. Sonke, et al.. (2015). Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy.. Journal of Clinical Oncology. 33(15_suppl). 2507–2507. 10 indexed citations

Leijen, Suzanne, Sjaak A. Burgers, Paul Baas, et al.. (2014). Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Investigational New Drugs. 33(1). 201–214. 321 indexed citations

Leijen, Suzanne, Stephan A. Veltkamp, Alwin D. R. Huitema, et al.. (2013). Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. Gynecologic Oncology. 130(3). 511–517. 8 indexed citations

Noll, Ruud van der, et al.. (2013). Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities. Cancer Treatment Reviews. 39(6). 664–672. 84 indexed citations

Leijen, Suzanne, Mark R. Middleton, Patricia Tresca, et al.. (2012). Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4794–4805. 55 indexed citations

10.

Xu, Yang, Wei Fang, Wei Zeng, Suzanne Leijen, & Eric Woolf. (2012). Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies. Analytical and Bioanalytical Chemistry. 404(10). 3037–3048. 31 indexed citations

11.

Rose, Shelonitda, Jonathan D. Cheng, Robert Iannone, et al.. (2012). Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.. Journal of Clinical Oncology. 30(15_suppl). e13598–e13598. 2 indexed citations

12.

Leijen, Suzanne, Patricia M.M.B. Soetekouw, T.R. Jeffry Evans, et al.. (2011). A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68(6). 1619–1628. 37 indexed citations

13.

Leijen, Suzanne, Mark R. Middleton, Patricia Tresca, et al.. (2011). Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.. Journal of Clinical Oncology. 29(15_suppl). 3017–3017. 7 indexed citations

14.

Schellens, J. H. M., Geoffrey I. Shapiro, Anne C. Pavlick, et al.. (2011). Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3068–3068. 14 indexed citations

15.

Leijen, Suzanne, Jos H. Beijnen, & Jan H.M. Schellens. (2010). Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents. Current Clinical Pharmacology. 5(3). 186–191. 90 indexed citations

16.

Leijen, Suzanne, Jan H.M. Schellens, Geoffrey I. Shapiro, et al.. (2010). A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3067–3067. 28 indexed citations

17.

Schellens, Jan H.M., Suzanne Leijen, Geoffrey I. Shapiro, et al.. (2009). A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3510–3510. 14 indexed citations

18.

Zwiers, Antonie, Ivan J. Fuss, Suzanne Leijen, et al.. (2008). Increased expression of the tight junction molecule claudin-18 A1 in both experimental colitis and ulcerative colitis. Inflammatory Bowel Diseases. 14(12). 1652–1659. 27 indexed citations

19.

Kummalue, Tanawan, et al.. (2004). AML1/RUNX1 Increases During G1 to S Cell Cycle Progression Independent of Cytokine-dependent Phosphorylation and Induces Cyclin D3 Gene Expression. Journal of Biological Chemistry. 279(15). 15678–15687. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact